RED TERAV - Investigadores

Investigadores

Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Investigadores
Publicaciones

Iolanda Jordan Garcia

Investigador principal

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Susana Rives Solà

Investigador principal

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

ALBERT CATALA TEMPRANO

Investigador colaborador

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Julio Castaño Cardoso

Investigador colaborador

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Laia Alsina Manrique de Lara

Investigador colaborador

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Mireia Camós Guijosa

Investigador colaborador

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Montserrat Torrebadell Burriel

Investigador colaborador

Grupo de Investigación: Hospital Sant Joan de Déu. Fundación para la Investigación y Docencia Sant Joan de Déu (HSJD/ FSJD)

Alonso-Saladrigues A., Esperanza-Cebollada E., Vicente-Garcés C., Perez-Jaume S., Sánchez-Sierra N., Richarte-Franqués M., Català A., Crespo-Carrasco A., Dapena J.L., Cuatrecasas Capdevila E., Faura Morros A., Ruiz-Cobo M.A., Arqués L., Conde Cuevas N., Andreu S., Isola I., Jordan I., García-Rey E., Llanos C., Marsal J., Celis V., Camós M., Torrebadell M., Vega-García N., Rives S.. Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy. Bone Marrow Transplantation. June 2026. DOI: 10.1038/s41409-026-02838-9.

Impacto: 5.2. Cuartil: Q1

Rivera-Pérez C., Morgades M., Alonso-Saladrigues A., Montesinos P., Murciano T., Gil C., Adán R., Esteve J., Fuentes C., Amigo M.L., González-Martínez B., Coll R., Dapena J.L., de Llano M.P.Q., Fuster J.L., García-Cadenas I., Tasso M., Barba P., Rives S., Ribera J.M.. Outcomes of pediatric and adult patients with relapsed/refractory cortical (CD1a+) T-cell acute lymphoblastic leukemia. The Spanish experience from SEHOP and PETHEMA groups. Annals of Hematology. April 2026. DOI: 10.1007/s00277-026-06956-8.

Impacto: 2.4. Cuartil: Q2

Alfonso-Comos P., Briz-Redón Á., Dapena Díaz J.L., Rives S., Fernández Navarro J.M., Verdú-Amorós J., Cañete A.. Spanish Paediatric Haematology and Oncology Survival Results and Trends, 1999–2022. Cancers. February 2026. DOI: 10.3390/cancers18030362.

Impacto: 4.4. Cuartil: Q2

Nafria B., Claverol J., Cubells M., Llanos C., Solé L., Sans E., López S., Catala-Mora J., Rives S., Morales A., Pineda M., García Cazorla À., Nascimento A., Morales M., Roe D., Fortuny C., Phillips B.. Cross-border access to clinical trials: participation of pediatric patients and language inclusion. Pediatric Research. 2026. DOI: 10.1038/s41390-026-04820-z.

Impacto: 3.1. Cuartil: Q1

Romero-Moya D., Torralba-Sales E., Calvo C., Marin-Bejar O., Magallon-Mosella M., Distefano M., Pera J., Castaño J., De Giorgio F., Gonzalez J., Iglesias A., Berenguer-Balaguer C., Schilling M., Plass M., Pasquali L., Català A., Molina O., Wlodarski M.W., Bigas A., Giorgetti A.. CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness. Leukemia. December 2025. DOI: 10.1038/s41375-025-02771-8.

Impacto: 13.4. Cuartil: Q1 (1er decil)

Pera J., Romero-Moya D., Torralba-Sales E., Andersson R., García-Hernández V., Magallon-Mosella M., Distefano M., Berenguer Balaguer C., Castaño J., De Giorgio F., Qiu Z., Iglesias A., Spurk P., Montserrat-Vazquez S., Pasquali L., Liang Z., Català A., Florian M.C., Wlodarski M.W., Bigas A., Marin-Bejar O., Giorgetti A.. Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency. Nature Communications. December 2025. DOI: 10.1038/s41467-025-65806-9.

Impacto: 15.7. Cuartil: Q1 (1er decil)

Galán-Gómez V., González-Martínez B., Alonso-Saladrigues A., Rives S., Herrero B., Kwon M., Sánchez-Pina J., Minguillón J., Martínez-Romera I., Mirones Aguilar I., Mestre-Durán C., Casado G., Sánchez-Martín M., Echecopar C., González-Pérez C., León-Triana O., Aguirre-Portolés C., Molinos-Quintana Á., Barba P., Balsalobre P., Pérez-Martínez A.. Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Experimental Hematology and Oncology. December 2025. DOI: 10.1186/s40164-025-00638-3.

Impacto: 9.4. Cuartil: Q1 (1er decil)

Rives S.. Point-of-care CAR T-cell therapy: toward broader access. Blood Advances. 14 October 2025. DOI: 10.1182/bloodadvances.2025017298.

Impacto: 7.1. Cuartil: Q1

Bartoló-Ibars A., Aran A., Johansson A.M., Ortiz-Maldonado V., Klein-González N., Alonso-Saladrigues A., James E., Urbano-Ispizua A., Rives S., Delgado J., González-Navarro E.A., Kwok W.W., Juan M.. T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes. Journal for Immunotherapy of Cancer. 22 September 2025. DOI: 10.1136/jitc-2024-010792.

Impacto: 10.6. Cuartil: Q1 (1er decil)

Awasthi R., Grupp S.A., Waldron E.R., Yanik G.A., Tam C.S., Rives S., McGuirk J.P., Pulsipher M.A., Jaeger U., Myers G.D., Borchmann P., Schuster S.J., Stefanski H.E., Bishop M.R., Chakraborty A., Masood A., Baruchel A., Waller E.K.. Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL. Blood Advances. 9 September 2025. DOI: 10.1182/bloodadvances.2024014995.

Impacto: 7.1. Cuartil: Q1

Silbert S.K., Rankin A.W., Hoang C.N., Semchenkova A., Myers R.M., Zerkalenkova E., Wang H.W., Kovach A.E., Yuan C.M., Delgado Colon D., Vasseur L., Bataller A., John S., Utley Lyons K., Friedes B., Alonso-Saladrigues A., Abdel-Azim H., Balducci E., Aljudi A.A., Balsat M., Biery D.N., Chamdin A., Chang B.H., Cuevo R.S., De Moerloose B., Dickens D.S., Duffner U., Duployez N., El Chaer F., Elliott M.A., Escherich G., Fernandes S., Fitzjohn M.R., Gahvari Z., Grupp S.A., He R.R., Harrison C., Hergott C.B., Hsieh E.M., Kim A.S., Kuo D.J., Larson D.P., Lee B.J., Leguay T., Lindsley R.C., Mangaonkar A.A., Mezger K., Pacenta H.L., Pan J., Provost M., Puri L., Raikar S.S., Martinez A., Bristol I., Murphy K., Reiman L., Redell M., Reed K., Roth-Guepin G., Rubinstein J., Savaşan S., Schafernak K., Stevens A., Talleur A., Torres Carapia N., Vargaftig J., Vatsayan A., Wölfl M., Zhao L., Rives S., Fabrizio V.A., Sasaki K., Aldoss I., Boissel N., Rheingold S.R., Davis K.L., Ghorashian S., Jacoby E., Popov A., Lamble A.J., Shah N.N.. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 24 July 2025. DOI: 10.1182/blood.2024026655.

Impacto: 23.1. Cuartil: Q1 (1er decil)

Sanchez-Sierra N., Alonso-Saladrigues A., Perez-Jaume S., Rivera-Perez C., Faura A., Arques L., Isola I.M., Torrebadell M., Diaz J.L.D., Rives S.. Platelet Counts Prior to Lymphodepletion Chemotherapy are Associated with Clinical Outcome in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After CAR-T19-Cell Therapy. Pediatric Blood and Cancer. May 2025. DOI: 10.1002/pbc.31604.

Impacto: 2.4. Cuartil: Q1

Pearson A.D.J., Rossig C., Mackall C.L., Shah N.N., Baruchel A., Daems S., Anderson J., Biondi A., Bird N., Bodmer N., Brivio E., Buechner J., Calkoen F.G., Cooper T., de Rojas T., Fox E., Gardner R., Ghorashian S., Heenen D., Ifversen M., Jacoby E., Juan M., Knox L., Komanduri K., Larghero J., Locatelli F., Ludwinski D., Majzner R.G., McDonough J., Minard-Colin V., Nysom K., Pappo A., Park J.R., Qasim W., Quintarelli C., Rives S., Rouce R.H., Scobie N., Seitz C., Tasian S.K., Weigel B., Weiner S., Zwaan C.M., Vassal G.. New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. The Lancet Oncology. April 2025. DOI: 10.1016/S1470-2045(24)00736-8.

Impacto: 41.6. Cuartil: Q1 (1er decil)

Guerrero-Murillo M., Rill-Hinarejos A., Trincado J.L., Bataller A., Ortiz-Maldonado V., Benítez-Ribas D., Español-Rego M., González-Navarro E.A., Martínez-Cibrián N., Marchese D., Martín-Martín L., García-Sancho A.M., Rives S., Heyn H., Juan M., Urbano-Ispizúa Á., Delgado J., Orfao A., Mereu E., Bueno C., Menendez P.. Erratum: Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias (Cell Reports Medicine (2024) 5(11), (S2666379124005500), (10.1016/j.xcrm.2024.101803)). Cell Reports Medicine. 18 March 2025. DOI: 10.1016/j.xcrm.2025.102026.

Impacto: 11.7. Cuartil: Q1 (1er decil)

Molinos-Quintana Á., Martínez-Cibrian N., Alonso-Saladrigues A., Galán-Gómez V., Bailén R., Buendía-López S., Fuentes-Socorro C., Kwon M., González-Vincent M., Pérez de Soto C., González-Martínez B., Rives S., Pérez-Hurtado J.M., Ortiz-Maldonado V., Pérez-Simón J.A.. Successful allogeneic CD34+ hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). Bone Marrow Transplantation. February 2025. DOI: 10.1038/s41409-024-02473-2.

Impacto: 4.5. Cuartil: Q1

Theron A., Alonso-Saladrigues A., Dapena J.L., López-Duarte M., Diaz de Heredia C., Verdú-Amorós J., Sarrate E., Esperanza-Cebollada E., Cuatrecasas E., Andreu S., Conde N., Sanchez-Sierra N., Isola I., Camós M., Torrebadell M., Rives S., Català A.. Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children. British Journal of Haematology. January 2025. DOI: 10.1111/bjh.19862.

Impacto: 5.1. Cuartil: Q1

Vicente-Garcés C., Fernández G., Esperanza-Cebollada E., Richarte-Franqués M., Crespo-Carrasco A., Montesdeoca S., Isola I., Sarrate E., Cuatrecasas E., Rives S., Dapena J.L., Camós M., Vega-García N.. RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia. British Journal of Haematology. 2025. DOI: 10.1111/bjh.20056.

Impacto: 5.1. Cuartil: Q1

Caballero-Bellón M., Bobillo-Perez S., Català A., Alonso-Saladrigues A., Valls A., Rives S., Jordan I.. Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults. Biomarkers. 2025. DOI: 10.1080/1354750X.2025.2454471.

Impacto: 1.9. Cuartil: Q3

Guerrero-Murillo M., Rill-Hinarejos A., Trincado J.L., Bataller A., Ortiz-Maldonado V., Benítez-Ribas D., Español-Rego M., González-Navarro E.A., Martínez-Cibrián N., Marchese D., Martín-Martín L., Martín García-Sancho A., Rives S., Heyn H., Juan M., Urbano-Ispizúa Á., Delgado J., Orfao A., Mereu E., Bueno C., Menendez P.. Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Reports Medicine. 19 November 2024. DOI: 10.1016/j.xcrm.2024.101803.

Impacto: 11.7. Cuartil: Q1 (1er decil)

Pennesi E., Brivio E., Ammerlaan A.C.J., Jiang Y., van der Velden V.H.J., Beverloo H.B., Sleight B., Locatelli F., Brethon B., Rossig C., Engstler G., Nilsson A., Bruno B., Petit A., Bielorai B., Rizzari C., Rialland F., Rubio-San-Simón A., Bautista Sirvent F.J., Diaz-De-Heredia C., Rives S., Zwaan C.M.. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematologica. October 2024. DOI: 10.3324/haematol.2023.284409.

Impacto: 8.2. Cuartil: Q1

Juan-Ribelles A., Bautista F., Cañete A., Rubio-San-Simón A., Alonso-Saladrigues A., Hladun R., Rives S., Dapena J.L., Fernández J.M., Lassaletta Á., Cruz O., Ramírez-Villar G., Fuster J.L., de Heredia C.D., García-Ariza M., Quiroga E., del Mar Andrés M., Verdú-Amorós J., Molinés A., Herrero B., López M., Márquez C., Toboso M., Lendínez F., Sirvent J.G., Tallón M., Rodríguez G., Acha T., Moreno L., Fernández-Teijeiro A.. ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer. Clinical and Translational Oncology. September 2024. DOI: 10.1007/s12094-024-03445-0.

Impacto: 2.8. Cuartil: Q2

Wu J.H., Pennesi E., Bautista F., Garrett M., Fukuhara K., Brivio E., Ammerlaan A.C.J., Locatelli F., van der Sluis I.M., Rossig C., Chen-Santel C., Bielorai B., Petit A., Starý J., Díaz-de-Heredia C., Rives S., O’Marcaigh A., Rizzari C., Engstler G., Nysom K., Rubio-San-Simón A., Bruno B., Bertrand Y., Brethon B., Rialland F., Plat G., Dirksen U., Sramkova L., Zwaan C.M., Huitema A.D.R.. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059. Clinical Pharmacokinetics. July 2024. DOI: 10.1007/s40262-024-01386-z.

Impacto: 4.6. Cuartil: Q1

Ruiz-Llobet A., Gassiot S., Sarrate E., Zubicaray J., Rives S., Suleman W., Berrueco R.. Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia. Thrombosis and Haemostasis. 17 May 2024. DOI: 10.1055/a-2316-4547.

Impacto: 5.0. Cuartil: Q1

López-Fernández A., Codinach M., Coca M.I., Prat-Vidal C., Castaño J., Torrents S., Aran G., Rodríguez L., Querol S., Vives J.. Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems. Cytotherapy. May 2024. DOI: 10.1016/j.jcyt.2023.08.008.

Impacto: 3.7. Cuartil: Q1

Rossig C., Pearson A.D., Vassal G., Scobie N., Bird N., Blanc P., Vormoor H.J., Calkoen F.G., Locatelli F., del Bufalo F., Rives S., Jacoby E., Balduzzi A., Bourquin J.P., Baruchel A.. Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed. Journal of Clinical Oncology. 20 January 2024. DOI: 10.1200/JCO.23.01314.

Impacto: 42.1. Cuartil: Q1 (1er decil)

Molinos-Quintana Á., Alonso-Saladrigues A., Herrero B., Caballero-Velázquez T., Galán-Gómez V., Panesso M., Torrebadell M., Delgado-Serrano J., Pérez de Soto C., Faura A., González-Martínez B., Castillo-Robleda A., Diaz-de-Heredia C., Pérez-Martínez A., Pérez-Hurtado J.M., Rives S., Pérez-Simón J.A.. Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring (Front. Immunol., (2024), 14, 1280580, 10.3389/fimmu.2023.1280580). Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1373852.

Impacto: 5.7. Cuartil: Q1

Petazzi P., Gutierrez-Agüera F., Roca-Ho H., Castaño J., Bueno C., Alvarez N., Forrester L.M., Sevilla A., Fidanza A., Menendez P.. Generation of an inducible dCas9-SAM human PSC line for endogenous gene activation. Frontiers in Cell and Developmental Biology. 2024. DOI: 10.3389/fcell.2024.1484955.

Impacto: 4.6. Cuartil: Q1

Rives S.. Central nervous system therapy in acute lymphoblastic leukemia: no more, no less. Haematologica. December 2023. DOI: 10.3324/haematol.2023.283275.

Impacto: 8.2. Cuartil: Q1

Kuebler B., Alvarez-Palomo B., Aran B., Castaño J., Rodriguez L., Raya A., Querol Giner S., Veiga A.. Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population. Stem Cell Research and Therapy. December 2023. DOI: 10.1186/s13287-023-03576-1.

Impacto: 7.1. Cuartil: Q1 (1er decil)

Marin-Bejar O., Romero-Moya D., Rodriguez-Ubreva J., Distefano M., Lessi F., Aretini P., Liquori A., Castaño J., Kozyra E., Kotmayer L., Bueno C., Cervera J., Rodriguez-Gallego J.C., Nomdedeu J.F., Murillo- Sanjuán L., de Heredia C.D., Pérez-Martinez A., López-Cadenas F., Martínez-Laperche C., Dorado-Herrero N., Marco F.M., Prósper F., Menendez P., Valcárcel D., Ballestar E., Bödör C., Bigas A., Catalá A., Wlodarski M.W., Giorgetti A.. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. Haematologica. September 2023. DOI: 10.3324/haematol.2022.282305.

Impacto: 8.2. Cuartil: Q1

Velasco P., Bautista F., Rubio A., Aguilar Y., Rives S., Dapena J.L., Pérez A., Ramirez M., Saiz-Ladera C., Izquierdo E., Escudero A., Camós M., Vega-García N., Ortega M., Hidalgo-Gómez G., Palacio C., Menéndez P., Bueno C., Montero J., Romecín P.A., Zazo S., Alvarez F., Parras J., Ortega-Sabater C., Chulián S., Rosa M., Cirillo D., García E., García J., Manzano-Muñoz A., Minguela A., Fuster J.L.. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP). Frontiers in Pediatrics. 22 August 2023. DOI: 10.3389/fped.2023.1269560.

Impacto: 2.1. Cuartil: Q2

Esperanza-Cebollada E., Gómez-González S., Perez-Jaume S., Vega-García N., Vicente-Garcés C., Richarte-Franqués M., Rives S., Català A., Torrebadell M., Camós M.. A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia. British Journal of Haematology. July 2023. DOI: 10.1111/bjh.18746.

Impacto: 5.1. Cuartil: Q1

Moreno C., Ramos-Elbal E., Velasco P., Aguilar Y., Gonzáález Martínez B., Fuentes C., Molinos Á., Guerra-García P., Palomo P., Verdu J., Adán Pedroso R.M., Vagace J.M., López-Duarte M., Regueiro A., Tasso M., Dapena J.L., Salinas J.A., Navarro S., Bautista F., Lassaletta Á., Lendínez F., Rives S., Pascual A., Rodríguez A., Pérez-Hurtado J.M., Fernández J.M., Pérez-Martínez A., González-Vicent M., Díaz de Heredia C., Fuster J.L.. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). Frontiers in Pediatrics. 3 May 2023. DOI: 10.3389/fped.2023.1140637.

Impacto: 2.1. Cuartil: Q2

Laetsch T.W., Maude S.L., Rives S., Hiramatsu H., Bittencourt H., Bader P., Baruchel A., Boyer M., De Moerloose B., Qayed M., Buechner J., Pulsipher M.A., Myers G.D., Stefanski H.E., Martin P.L., Nemecek E., Peters C., Yanik G., Khaw S.L., Davis K.L., Krueger J., Balduzzi A., Boissel N., Tiwari R., O'Donovan D., Grupp S.A.. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Journal of Clinical Oncology. 20 March 2023. DOI: 10.1200/JCO.22.00642.

Impacto: 42.1. Cuartil: Q1 (1er decil)

Molinos-Quintana Á., Alonso-Saladrigues A., Herrero B., Caballero-Velázquez T., Galán-Gómez V., Panesso M., Torrebadell M., Delgado-Serrano J., Pérez de Soto C., Faura A., González-Martínez B., Castillo-Robleda A., Diaz-de-Heredia C., Pérez-Martínez A., Pérez-Hurtado J.M., Rives S., Pérez-Simón J.A.. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1280580.

Impacto: 5.7. Cuartil: Q1

Caballero-Bellón M., Alonso-Saladrigues A., Bobillo-Perez S., Faura A., Arqués L., Rivera C., Català A., Dapena J.L., Rives S., Jordan I.. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1219289.

Impacto: 5.7. Cuartil: Q1

Vicente-Garcés C., Maynou J., Fernández G., Esperanza-Cebollada E., Torrebadell M., Català A., Rives S., Camós M., Vega-García N.. Fusion InPipe, an integrative pipeline for gene fusion detection from RNA-seq data in acute pediatric leukemia. Frontiers in Molecular Biosciences. 2023. DOI: 10.3389/fmolb.2023.1141310.

Impacto: 3.9. Cuartil: Q2

Ghorashian S., Jacoby E., De Moerloose B., Rives S., Bonney D., Shenton G., Bader P., Bodmer N., Quintana A.M., Herrero B., Algeri M., Locatelli F., Vettenranta K., Gonzalez B., Attarbaschi A., Harris S., Bourquin J.P., Baruchel A.. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. The Lancet Haematology. October 2022. DOI: 10.1016/S2352-3026(22)00225-3.

Impacto: 24.7. Cuartil: Q1 (1er decil)

Tong W.H., Mesegué M., Dapena J.L., Camós M., Rives S.. Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia. Hematological Oncology. October 2022. DOI: 10.1002/hon.2960.

Impacto: 3.3. Cuartil: Q2

Pera J., Castaño J., Casamitjana J., Giorgetti A., Romero-Moya D.. Generation of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying p.I1567M mutation. Stem Cell Research. October 2022. DOI: 10.1016/j.scr.2022.102906.

Impacto: 1.2. Cuartil: Q4

Bueno C., Barrera S., Bataller A., Ortiz-Maldonado V., Elliot N., O'Byrne S., Wang G., Rovira M., Gutierrez-Agüera F., Trincado J.L., González-González M., Morgades M., Sorigué M., Bárcena P., Zanetti S.R., Torrebadell M., Vega-Garcia N., Rives S., Mallo M., Sole F., Mead A.J., Roberts I., Thongjuea S., Psaila B., Juan M., Delgado J., Urbano-Ispizúa A., Ribera J.M., Orfao A., Roy A., Menendez P.. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood. 7 July 2022. DOI: 10.1182/blood.2021014840.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Laetsch T.W., Maude S.L., Balduzzi A., Rives S., Bittencourt H., Boyer M.W., Buechner J., De Moerloose B., Qayed M., Phillips C.L., Pulsipher M.A., Hiramatsu H., Tiwari R., Grupp S.A.. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. June 2022. DOI: 10.1038/s41375-022-01550-z.

Impacto: 11.4. Cuartil: Q1 (1er decil)

Ruiz-Llobet A., Gassiot S., Sarrate E., Zubicaray J., Dapena J.L., Rives S., Sevilla J., Menárguez López Á., Panesso Romero M., Montoya C., Vagace J.M., Molina Hurtado J.R., García-Morín M., García Abós M., Mendoza Sánchez M.C., Lendínez F., Palomo Moraleda P., Tallón M., González B., Urrutia E., Serna J.V., Peláez Pleguezuelos I., Martínez Merino M., Ramos Elbal E., Orellana E., Benítez Muñoz H., Berrueco R.. Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013. Journal of Thrombosis and Haemostasis. June 2022. DOI: 10.1111/jth.15699.

Impacto: 10.4. Cuartil: Q1 (1er decil)

Ortiz-Maldonado V., Alonso-Saladrigues A., Español-Rego M., Martínez-Cibrián N., Faura A., Magnano L., Català A., Benítez-Ribas D., Giné E., Díaz-Beyá M., Correa J.G., Rovira M., Montoro-Lorite M., Martínez-Roca A., Rodríguez-Lobato L.G., Cabezón R., Cid J., Lozano M., Garcia-Rey E., Conde N., Pedrals G., Rozman M., Torrebadell M., Setoain X., Rodríguez S., Esteve J., Pascal M., Urbano-Ispizua Á., Juan M., Delgado J., Rives S.. Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology. 1 June 2022. DOI: 10.1002/ajh.26519.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Pennesi E., Michels N., Brivio E., van der Velden V.H.J., Jiang Y., Thano A., Ammerlaan A.J.C., Boer J.M., Beverloo H.B., Sleight B., Chen Y., Vormoor-Bürger B., Rives S., Bielorai B., Rössig C., Petit A., Rizzari C., Engstler G., Starý J., Bautista Sirvent F.J., Chen-Santel C., Bruno B., Bertrand Y., Rialland F., Plat G., Reinhardt D., Vinti L., Von Stackelberg A., Locatelli F., Zwaan C.M.. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. June 2022. DOI: 10.1038/s41375-022-01576-3.

Impacto: 11.4. Cuartil: Q1 (1er decil)

Domingo-Reinés J., Martínez-Navajas G., Montes R., Lamolda M., Simón I., Castaño J., Ríos-Pelegrina R., Lopez-Hidalgo J.L., García del Moral R., Marchal J.A., Real P.J., Ramos-Mejía V.. Generation of a H9 Clonal Cell Line With Inducible Expression of NUP98-KDM5A Fusion Gene in the AAVS1 Safe Harbor Locus. Frontiers in Cell and Developmental Biology. 1 June 2022. DOI: 10.3389/fcell.2022.846092.

Impacto: 5.5. Cuartil: Q1

Vicente-Garcés C., Esperanza-Cebollada E., Montesdeoca S., Torrebadell M., Rives S., Dapena J.L., Català A., Conde N., Camós M., Vega-García N.. Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia. Frontiers in Molecular Biosciences. 7 April 2022. DOI: 10.3389/fmolb.2022.854098.

Impacto: 5.0. Cuartil: Q2

Buchmann S., Schrappe M., Baruchel A., Biondi A., Borowitz M., Campbell M., Cario G., Cazzaniga G., Escherich G., Harrison C.J., Heyman M., Hunger S.P., Kiss C., Liu H.C., Locatelli F., Loh M.L., Manabe A., Mann G., Pieters R., Pui C.H., Rives S., Schmiegelow K., Silverman L.B., Stary J., Vora A., Brown P.. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 24 March 2022. DOI: 10.1182/blood.2021012328.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Lopez-Millan B., Costales P., Gutiérrez-Agüera F., de la Guardia R.D., Roca-Ho H., Vinyoles M., Rubio-Gayarre A., Safi R., Castaño J., Romecín P.A., Ramírez-Orellana M., Anguita E., Jeremias I., Zamora L., Rodríguez-Manzaneque J.C., Bueno C., Morís F., Menendez P.. The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. Cancers. March-2 2022. DOI: 10.3390/cancers14061593.

Impacto: 5.2. Cuartil: Q2

Caballero M., Faura A., Margarit A., Bobillo-Perez S., Català A., Alonso-Saladrigues A., Conde N., Balaguer M., Rives S., Jordan I.. Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit. European Journal of Pediatrics. March 2022. DOI: 10.1007/s00431-021-04292-9.

Impacto: 3.6. Cuartil: Q1

Buechner J., Caruana I., Künkele A., Rives S., Vettenranta K., Bader P., Peters C., Baruchel A., Calkoen F.G.. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics. 25 January 2022. DOI: 10.3389/fped.2021.784024.

Impacto: 2.6. Cuartil: Q2

Pulsipher M.A., Han X., Maude S.L., Laetsch T.W., Qayed M., Rives S., Boyer M.W., Hiramatsu H., Yanik G.A., Driscoll T., Myers G.D., Bader P., Baruchel A., Buechner J., Stefanski H.E., Kalfoglou C., Nguyen K., Waldron E.R., Mueller K.T., Maier H.J., Kari G., Grupp S.A.. Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discovery. 1 January 2022. DOI: 10.1158/2643-3230.BCD-21-0095.

Ortiz-Maldonado V., Rives S., Español-Rego M., Alonso-Saladrigues A., Montoro M., Magnano L., Giné E., Pascal M., Diáz-Beyá M., Castella M., Català A., Faura A., Rodríguez-Lobato L.G., Oliver-Caldes A., Martínez-Roca A., Rovira M., González-Navarro E.A., Ortega J.R., Cid J., Lozano M., Garcia-Rey E., Fernández S., Castro P., Jordan I., Villamor N., Aymerich M., Torrebadell M., Deyà À., De Larrea C.F., Benitez-Ribas D., Trias E., Varea S., Calvo G., Esteve J., Urbano-Ispizua A., Juan M., Delgado J.. Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. Journal for ImmunoTherapy of Cancer. 1 December 2021. DOI: 10.1136/jitc-2021-003644.

Impacto: 12.469. Cuartil: Q1 (1er decil)

Mesegué M., Alonso-Saladrigues A., Pérez-Jaume S., Comes-Escoda A., Dapena J.L., Faura A., Conde N., Català A., Ruiz-Llobet A., Zapico-Muñiz E., Camós M., Rives S.. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia. Hematological Oncology. December 2021. DOI: 10.1002/hon.2914.

Impacto: 4.85. Cuartil: Q2

Maroni G., Bassal M.A., Krishnan I., Fhu C.W., Savova V., Zilionis R., Maymi V.A., Pandell N., Csizmadia E., Zhang J., Storti B., Castaño J., Panella R., Li J., Gustafson C.E., Fox S., Levy R.D., Meyerovitz C.V., Tramontozzi P.J., Vermilya K., De Rienzo A., Crucitta S., Bassères D.S., Weetall M., Branstrom A., Giorgetti A., Ciampi R., Del Re M., Danesi R., Bizzarri R., Yang H., Kocher O., Klein A.M., Welner R.S., Bueno R., Magli M.C., Clohessy J.G., Ali A., Tenen D.G., Levantini E.. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Communications Biology. December 2021. DOI: 10.1038/s42003-021-01897-6.

Impacto: 6.548. Cuartil: Q1

Rubio-San-Simón A., Hladun Alvaro R., Juan Ribelles A., Castañeda Heredia A., Guerra-García P., Verdú-Amorós J., Andrés M., Cañete A., Rives S., Pérez-Martínez A., Mora J., Patiño-García A., Lassaleta A., Llort A., Ramírez M., Mata C., Gallego S., Martín-Broto J., Cruz O., Morales La Madrid A., Solano P., Martínez Romera I., Fernández‑Teijeiro A., Bautista F., Moreno L.. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology. December 2021. DOI: 10.1007/s12094-021-02649-y.

Impacto: 3.34. Cuartil: Q3

Ruiz de Garibay G., Fernandez-Garcia I., Mazoyer S., Leme de Calais F., Ameri P., Vijayakumar S., Martinez-Ruiz H., Damiola F., Barjhoux L., Thomassen M., Andersen L.v.B., Herranz C., Mateo F., Palomero L., Espín R., Gómez A., García N., Jimenez D., Bonifaci N., Extremera A.I., Castaño J., Raya A., Eyras E., Puente X.S., Brunet J., Lázaro C., Radice P., Barnes D.R., Antoniou A.C., Spurdle A.B., de la Hoya M., Baralle D., Barcellos-Hoff M.H., Pujana M.A.. Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. Human Mutation. November 2021. DOI: 10.1002/humu.24276.

Impacto: 4.7. Cuartil: Q2

Rives S.. CAR T cells in CNS-relapsed leukaemia: one step forward. The Lancet Haematology. October 2021. DOI: 10.1016/S2352-3026(21)00281-7.

Impacto: 30.153. Cuartil: Q1 (1er decil)

Fuster J.L., Bautista F., González B., Fernández J.M., Rives S., Dapena J.L.. Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia. Clinical and Translational Oncology. September 2021. DOI: 10.1007/s12094-021-02590-0.

Impacto: 3.34. Cuartil: Q3

Levine J.E., Grupp S.A., Pulsipher M.A., DIetz A.C., Rives S., Myers G.D., August K.J., Verneris M.R., Buechner J., Laetsch T.W., Bittencourt H., Baruchel A., Boyer M.W., De Moerloose B., Qayed M., Davies S.M., Phillips C.L., Driscoll T.A., Bader P., Schlis K., Wood P.A., Mody R., Yi L., Leung M., Eldjerou L.K., June C.H., Maude S.L.. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. Journal for ImmunoTherapy of Cancer. 5 August 2021. DOI: 10.1136/jitc-2020-002287.

Impacto: 12.469. Cuartil: Q1 (1er decil)

Castaño J., Romero-Moya D., Richaud-Patin Y., Giorgetti A.. Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency. Stem Cell Research. August 2021. DOI: 10.1016/j.scr.2021.102445.

Impacto: 1.587. Cuartil: Q4

Niemeyer C.M., Flotho C., Lipka D.B., Stary J., Rössig C., Baruchel A., Klingebiel T., Micalizzi C., Michel G., Nysom K., Rives S., Liner M.S., Zecca M., Schönung M., Baumann I., Nöllke P., Benettaib B., Biserna N., Poon J., Simcock M., Patturajan M., Menezes D., Gaudy A., Van Den Heuvel-Eibrink M.M., Locatelli F.. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Advances. 27 July 2021. DOI: 10.1182/bloodadvances.2020004144.

Impacto: 7.637. Cuartil: Q1

Vega-García N., Perez-Jaume S., Esperanza-Cebollada E., Vicente-Garcés C., Torrebadell M., Jiménez-Velasco A., Ortega M., Llop M., Abad L., Vagace J.M., Minguela A., Pratcorona M., Sánchez-Garcia J., García-Calderón C.B., Gómez-Casares M.T., Martín-Clavero E., Escudero A., Riñón Martinez-Gallo M., Muñoz L., Velasco M.R., García-Morin M., Català A., Pascual A., Velasco P., Fernández J.M., Lassaletta A., Fuster J.L., Badell I., Molinos-Quintana Á., Molinés A., Guerra-García P., Pérez-Martínez A., García-Abós M., Robles Ortiz R., Pisa S., Adán R., Díaz de Heredia C., Dapena J.L., Rives S., Ramírez-Orellana M., Camós M.. Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. Frontiers in Pediatrics. 5 February 2021. DOI: 10.3389/fped.2020.614521.

Impacto: 3.569. Cuartil: Q2

Ortíz-Maldonado V., Rives S., Castellà M., Alonso-Saladrigues A., Benítez-Ribas D., Caballero-Baños M., Baumann T., Cid J., Garcia-Rey E., Llanos C., Torrebadell M., Villamor N., Giné E., Díaz-Beyá M., Guardia L., Montoro M., Català A., Faura A., González E.A., Español-Rego M., Klein-González N., Alsina L., Castro P., Jordan I., Fernández S., Ramos F., Suñé G., Perpiñá U., Canals J.M., Lozano M., Trias E., Scalise A., Varea S., Sáez-Peñataro J., Torres F., Calvo G., Esteve J., Urbano-Ispizua Á., Juan M., Delgado J.. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. Molecular Therapy. 3 February 2021. DOI: 10.1016/j.ymthe.2020.09.027.

Impacto: 12.91. Cuartil: Q1 (1er decil)

Deyà-Martínez A., Alonso-Saladrigues A., García A.P., Faura A., Torrebadell M., Vlagea A., Català A., Esteve-Solé A., Juan M., Rives S., Alsina L.. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplantation. February 2021. DOI: 10.1038/s41409-020-01027-6.

Impacto: 5.174. Cuartil: Q2

Buechner J., Grupp S.A., Hiramatsu H., Teachey D.T., Rives S., Laetsch T.W., Yanik G.A., Wood P., Awasthi R., Yi L., Chassot-Agostinho A., Eldjerou L.K., De Moerloose B.. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances. 26 January 2021. DOI: 10.1182/bloodadvances.2020002757.

Impacto: 7.637. Cuartil: Q1

Vega-Garcia N., Benito R., Esperanza-Cebollada E., Llop M., Robledo C., Vicente-Garcés C., Alonso J., Barragán E., Fernández G., Hernández-Sánchez J.M., Martín-Izquierdo M., Maynou J., Minguela A., Montaño A., Ortega M., Torrebadell M., Cervera J., Sánchez J., Jiménez-Velasco A., Riesco S., Hernández-Rivas J.M., Lassaletta Á., Fernández J.M., Rives S., Dapena J.L., Ramírez M., Camós M.. Helpful criteria when implementing ngs panels in childhood lymphoblastic leukemia. Journal of Personalized Medicine. November 2020. DOI: 10.3390/jpm10040244.

Impacto: 4.945. Cuartil: Q1

Faura A., Rives S., Lassaletta Á., Sebastián E., Madero L., Huerta J., García-Morín M., Martínez A.P., Sisinni L., Astigarraga I., Velasco P., Gros L., Moreno L., Carboné A., Rodríguez-Vigil C., Riesco S., Mendoza M.d.C., Macias E.G., Trabazo M., Torrent M., Badell I., Fuster J.L., Dominguez-Pinilla N., Juan Ribelles A., Pérez-Alonso V., Fernández Sanmartín M., Baragaño M., Gorostegui M., Perez-Jaume S., Fernández-Teijeiro A., Morales La Madrid A., Dapena J.L.. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatric Blood and Cancer. 1 September 2020. DOI: 10.1002/pbc.28557.

Impacto: 3.167. Cuartil: Q1

Fuster J.L., Molinos-Quintana A., Fuentes C., Fernández J.M., Velasco P., Pascual T., Rives S., Dapena J.L., Sisinni L., López-Godino O., Palomo P., Villa-Alcázar M., Bautista F., González-Vicent M., López-Duarte M., García-Morín M., Ramos-Elbal E., Ramírez M.. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). British Journal of Haematology. 1 September 2020. DOI: 10.1111/bjh.16647.

Impacto: 6.998. Cuartil: Q1

Juan M., Rives S.. CAR-T immunotherapy in pediatric hemato-oncology… present and future. Anales de Pediatria. July 2020. DOI: 10.1016/j.anpedi.2020.04.023.

Impacto: 1.5. Cuartil: Q4

Mirones I., Moreno L., Patiño-García A., Lizeaga G., Moraleda J.M., Toribio M.L., Pérez-Martínez A., Sisinni L., García-Morín M., Anguita J., Ramírez M., Díaz M.Á., González M., Alonso L., Rives S., Alonso M.M., Palomo P., Verdú-Amorós J., Martínez I., Guerra-García P., Fuster J.L., Sánchez-Salinas A., Blanquer M., García-Castro J., van Santen H.M., Menéndez P.. Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales de Pediatria. July 2020. DOI: 10.1016/j.anpedi.2019.12.014.

Impacto: 1.5. Cuartil: Q4

Baroni M.L., Martinez D.S., Aguera F.G., Ho H.R., Castella M., Zanetti S.R., Hernandez T.V., de la Guardia R.D., Castaño J., Anguita E., Vives S., Nomdedeu J., Lapillone H., Bras A.E., van der Velden V.H.J., Junca J., Marin P., Bataller A., Esteve J., Vick B., Jeremias I., Lopez A., Sorigue M., Bueno C., Menendez P.. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. Journal for ImmunoTherapy of Cancer. 10 June 2020. DOI: 10.1136/jitc-2020-000845.

Impacto: 13.751. Cuartil: Q1 (1er decil)

Petazzi P., Torres-Ruiz R., Fidanza A., Roca-Ho H., Gutierrez-Agüera F., Castaño J., Rodriguez-Perales S., Díaz de la Guardia R., López-Millán B., Bigas A., Forrester L.M., Bueno C., Menéndez P.. Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells. Molecular Therapy Nucleic Acids. 5 June 2020. DOI: 10.1016/j.omtn.2020.02.009.

Impacto: 8.886. Cuartil: Q1 (1er decil)

Hrusak O., Kalina T., Wolf J., Balduzzi A., Provenzi M., Rizzari C., Rives S., del Pozo Carlavilla M., Alonso M.E.V., Domínguez-Pinilla N., Bourquin J.P., Schmiegelow K., Attarbaschi A., Grillner P., Mellgren K., van der Werff ten Bosch J., Pieters R., Brozou T., Borkhardt A., Escherich G., Lauten M., Stanulla M., Smith O., Yeoh A.E.J., Elitzur S., Vora A., Li C.K., Ariffin H., Kolenova A., Dallapozza L., Farah R., Lazic J., Manabe A., Styczynski J., Kovacs G., Ottoffy G., Felice M.S., Buldini B., Conter V., Stary J., Schrappe M.. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer. June 2020. DOI: 10.1016/j.ejca.2020.03.021.

Impacto: 9.162. Cuartil: Q1

Castella M., Caballero-Baños M., Ortiz-Maldonado V., González-Navarro E.A., Suñé G., Antoñana-Vidósola A., Boronat A., Marzal B., Millán L., Martín-Antonio B., Cid J., Lozano M., García E., Tabera J., Trias E., Perpiña U., Canals J.M., Baumann T., Benítez-Ribas D., Campo E., Yagüe J., Urbano-Ispizua Á., Rives S., Delgado J., Juan M.. Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase i clinical trial. Frontiers in Immunology. 2020. DOI: 10.3389/fimmu.2020.00482.

Impacto: 7.561. Cuartil: Q1

Laetsch T.W., Myers G.D., Baruchel A., Dietz A.C., Pulsipher M.A., Bittencourt H., Buechner J., De Moerloose B., Davis K.L., Nemecek E., Driscoll T., Mechinaud F., Boissel N., Rives S., Bader P., Peters C., Sabnis H.S., Grupp S.A., Yanik G.A., Hiramatsu H., Stefanski H.E., Rasouliyan L., Yi L., Shah S., Zhang J., Harris A.C.. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. The Lancet Oncology. December 2019. DOI: 10.1016/S1470-2045(19)30493-0.

Impacto: 33.752. Cuartil: Q1 (1er decil)

Bautista F., Cañete A., Ramírez-Villar G.L., Fernández J.M., Fuster J.L., Diaz de Heredia C., Astigarraga I., García-Ariza M., Rives S., Dapena J.L., Márquez C., Molinés A., Bermúdez M.d.M., Gallego S., Andrés M.d.M., Verdu-Amoros J., Hernández C., López M., Catalá A., Lassaletta , Cruz O., Ramírez M., Lendínez F., Carboné A., Gomez Sirvent J., Tallón M., Acha T., Moreno L., Fernández-Teijeiro A.. ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clinical and Translational Oncology. 1 December 2019. DOI: 10.1007/s12094-019-02221-9.

Impacto: 2.737. Cuartil: Q3

Castaño J., Aranda S., Bueno C., Calero-Nieto F.J., Mejia-Ramirez E., Mosquera J.L., Blanco E., Wang X., Prieto C., Zabaleta L., Mereu E., Rovira M., Jiménez-Delgado S., Matson D.R., Heyn H., Bresnick E.H., Göttgens B., Di Croce L., Menendez P., Raya A., Giorgetti A.. GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm. Stem Cell Reports. 10 September 2019. DOI: 10.1016/j.stemcr.2019.07.009.

Impacto: 6.032. Cuartil: Q1

Cabezas M., Camós M., Rives S., Garcia-Orad A., Lopez-Lopez E., Dapena J.L., Caballín M.R., Armengol G.. Impact of polymorphisms in apoptosis-related genes on the outcome of childhood acute lymphoblastic leukaemia. British Journal of Haematology. April 2019. DOI: 10.1111/bjh.15415.

Impacto: 5.518. Cuartil: Q1

Arellano-Viera E., Zabaleta L., Castaño J., Azkona G., Carvajal-Vergara X., Giorgetti A.. Generation of two transgene-free human iPSC lines from CD133 + cord blood cells. Stem Cell Research. April 2019. DOI: 10.1016/j.scr.2019.101410.

Impacto: 4.495. Cuartil: Q1

Castella M., Boronat A., Martín-Ibáñez R., Rodríguez V., Suñé G., Caballero M., Marzal B., Pérez-Amill L., Martín-Antonio B., Castaño J., Bueno C., Balagué O., González-Navarro E.A., Serra-Pages C., Engel P., Vilella R., Benitez-Ribas D., Ortiz-Maldonado V., Cid J., Tabera J., Canals J.M., Lozano M., Baumann T., Vilarrodona A., Trias E., Campo E., Menendez P., Urbano-Ispizua Á., Yagüe J., Pérez-Galán P., Rives S., Delgado J., Juan M.. Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy Methods and Clinical Development. 15 March 2019. DOI: 10.1016/j.omtm.2018.11.010.

Impacto: 4.533. Cuartil: Q1

Vega-García N., Malatesta R., Estella C., Pérez-Jaume S., Esperanza-Cebollada E., Torrebadell M., Català A., Gassiot S., Berrueco R., Ruiz-Llobet A., Alonso-Saladrigues A., Mesegué M., Pont-Martí S., Rives S., Camós M.. Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases. British Journal of Haematology. August 2018. DOI: 10.1111/bjh.15436.

Impacto: 5.206. Cuartil: Q1

Ludwig Sanz-Orrio G., Noguera-Julian A., Rives Solá S., Gené Giralt A.. Blood culture time to positivity in oncology pediatric patients. Enfermedades Infecciosas y Microbiologia Clinica. May 2018. DOI: 10.1016/j.eimc.2017.09.008.

Impacto: 1.685. Cuartil: Q4

Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P., Verneris M.R., Stefanski H.E., Myers G.D., Qayed M., De Moerloose B., Hiramatsu H., Schlis K., Davis K.L., Martin P.L., Nemecek E.R., Yanik G.A., Peters C., Baruchel A., Boissel N., Mechinaud F., Balduzzi A., Krueger J., June C.H., Levine B.L., Wood P., Taran T., Leung M., Mueller K.T., Zhang Y., Sen K., Lebwohl D., Pulsipher M.A., Grupp S.A.. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 1 February 2018. DOI: 10.1056/NEJMoa1709866.

Impacto: 70.67. Cuartil: Q1 (1er decil)

Montoya Tamayo C., Bossacoma Busquets F., Vinent Genestar J., Fortuny Guasch C., Santa-Maria López V., Rives S.. Intravenous pentamidine for Pneumocystis pneumonia prophylaxis in children undergoing autologous hematopoietic stem cell transplant. Pediatric Blood and Cancer. November 2017. DOI: 10.1002/pbc.26558.

Impacto: 2.646. Cuartil: Q1

Romero-Moya D., Castaño J., Santos-Ocaña C., Navas P., Menendez P.. Generation, genome edition and characterization of iPSC lines from a patient with coenzyme Q<inf>10</inf> deficiency harboring a heterozygous mutation in COQ4 gene. Stem Cell Research. October 2017. DOI: 10.1016/j.scr.2016.09.007.

Impacto: 1.829. Cuartil: Q3

Bautista F., Gallego S., Cañete A., Mora J., Díaz de Heredia C., Cruz O., Fernández J.M., Rives S., Berlanga P., Hladun R., Juan Ribelles A., Madero L., Ramírez M., Fernández Delgado R., Pérez-Martínez A., Mata C., Llort A., Martín Broto J., Cela M.E., Ramírez G., Sábado C., Acha T., Astigarraga I., Sastre A., Muñoz A., Guibelalde M., Moreno L.. Early clinical trials in paediatric oncology in Spain: a nationwide perspective. Anales de Pediatria. September 2017. DOI: 10.1016/j.anpedi.2016.07.007.

Impacto: 1.318. Cuartil: Q3

Gentilella A., Morón-Duran F.D., Fuentes P., Rocha G.Z., Riaño-Canalias F., Pelletier J., Ruiz M., Turón G., Castaño J., Tauler A., Bueno C., Menéndez P., Kozma S.C., Thomas G.. Autogenous Control of 5′TOP mRNA Stability by 40S Ribosomes. Molecular Cell. 6 July 2017. DOI: 10.1016/j.molcel.2017.06.005.

Impacto: 14.248. Cuartil: Q1 (1er decil)

Romero-Moya D., Santos-Ocaña C., Castaño J., Garrabou G., Rodríguez-Gómez J.A., Ruiz-Bonilla V., Bueno C., González-Rodríguez P., Giorgetti A., Perdiguero E., Prieto C., Moren-Nuñez C., Fernández-Ayala D.J., Victoria Cascajo M., Velasco I., Canals J.M., Montero R., Yubero D., Jou C., López-Barneo J., Cardellach F., Muñoz-Cánoves P., Artuch R., Navas P., Menendez P.. Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells Model of Coenzyme Q<inf>10</inf> Deficiency. Stem Cells. July 2017. DOI: 10.1002/stem.2634.

Impacto: 5.587. Cuartil: Q1 (1er decil)

Diaz de la Guardia R., Lopez-Millan B., Lavoie J.R., Bueno C., Castaño J., Gómez-Casares M., Vives S., Palomo L., Juan M., Delgado J., Blanco M.L., Nomdedeu J., Chaparro A., Fuster J.L., Anguita E., Rosu-Myles M., Menéndez P.. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. Stem Cell Reports. 6 June 2017. DOI: 10.1016/j.stemcr.2017.04.019.

Impacto: 6.537. Cuartil: Q1

Torres-Ruiz R., Martinez-Lage M., Martin M.C., Garcia A., Bueno C., Castaño J., Ramirez J.C., Menendez P., Cigudosa J.C., Rodriguez-Perales S.. Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9. Stem Cell Reports. 9 May 2017. DOI: 10.1016/j.stemcr.2017.04.014.

Impacto: 6.537. Cuartil: Q1

de Sevilla M.F., Català A., Rives S., Berrueco R., Vidiella N., Camós M., Torrebadell M., Alonso-Saladrigues A., Mesegué M., Ruiz-Llobet A., Blanco-Álvarez A., Benéitez D.. Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions. Pediatric Blood and Cancer. 1 May 2017. DOI: 10.1002/pbc.26317.

Impacto: 2.646. Cuartil: Q1

Castaño J., Bueno C., Jiménez-Delgado S., Roca-Ho H., Fraga M.F., Fernandez A.F., Nakanishi M., Torres-Ruiz R., Rodríguez-Perales S., Menéndez P.. Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the “safe harbor” AAVS1 locus. Stem Cell Research. 1 May 2017. DOI: 10.1016/j.scr.2017.04.011.

Impacto: 1.829. Cuartil: Q3

Barba P., Dapena J.L., Montesinos P., Rives S.. Asparaginase use for the treatment of acute lymphoblastic leukemia. Medicina Clinica. 3 March 2017. DOI: 10.1016/j.medcli.2016.12.006.

Impacto: 1.168. Cuartil: Q3

Monsonís Cabedo M., Rives Solá S., Noguera-Julian A., Urrea Ayala M., Cruz Martinez O., Gené Giralt A.. Assessment of anaerobic blood cultures in pediatric oncology patients. Enfermedades Infecciosas y Microbiologia Clinica. 1 January 2017. DOI: 10.1016/j.eimc.2016.04.009.

Impacto: 1.707. Cuartil: Q3

Giorgetti A., Castaño J., Bueno C., Díaz de la Guardia R., Delgado M., Bigas A., Espinosa L., Menendez P.. Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. Experimental Hematology. 1 January 2017. DOI: 10.1016/j.exphem.2016.09.007.

Impacto: 2.436. Cuartil: Q3

Solanas G., Miravet S., Casagolda D., Castaño J., Raurell I., Corrionero A., García De Herreros A., Duñach M.. Erratum: β-Catenin and plakoglobin N- and C-tails determine ligand specificity (Journal of Biological Chemistry (2016) 279 (49849-49856) DOI: 10.1074/jbc.M408685200). Journal of Biological Chemistry. 11 November 2016. DOI: 10.1074/jbc.A116.408685.

Impacto: 4.125. Cuartil: Q2

Bruzos-Cidon C., Castaño J., Torrecilla M., Sanchez-Pernaute R., Giorgetti A.. Fast and efficient neural conversion of human hematopoietic cells. Current Protocols in Stem Cell Biology. November 2016. DOI: 10.1002/cpsc.16.

Rovira N., Noguera-Julian A., Rives S., Berrueco R., Lahoz R., Fortuny C.. Influence of new antiretrovirals on hematological toxicity in HIV-exposed uninfected infants. European Journal of Pediatrics. 1 July 2016. DOI: 10.1007/s00431-016-2730-x.

Impacto: 1.921. Cuartil: Q2

Bautista F., Gallego S., Cañete A., Mora J., Diaz de Heredia C., Cruz O., Fernández J.M., Rives S., Madero L., Castel V., Cela M.E., Ramírez G., Sábado C., Acha T., Astigarraga I., Sastre A., Muñoz A., Guibelalde M., Moreno L.. Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology. 1 July 2016. DOI: 10.1007/s12094-015-1421-9.

Impacto: 2.353. Cuartil: Q3